Empiric radioiodine for hyperthyroidism: Outcomes, prescribing patterns, and its place in the modern era of theranostics.

BACKGROUND: The modern era of radioiodine (I-131) theranostics for metastatic differentiated thyroid cancer requires us to rationalize the role of traditional empiric prescription in nonmalignant thyroid disease. We currently practice empiric I-131 prescription for treatment of hyperthyroidism. This study aims to assess outcomes after treatment of hyperthyroidism by empiric I-131 prescription at our centre, evaluate factors that impact on outcomes and prescribing practice, and gain insight into whether there is a place for theranostically-guided prescription in hyperthyroidism. PATIENTS AND METHODS: A retrospective review was undertaken of all patients with Graves' disease, toxic multinodular goitre (MNG) and toxic adenoma treated with I-131 between 2016 and 2021. Associations between clinical or scintigraphic variables and remission (euthyroid or hypothyroid) or persistence of hyperthyroidism at follow-up were performed using standard t test as well as Pearson's product correlation. RESULTS: Of 146 patients with a mean follow-up of 13.6 months, 80.8% achieved remission of hyperthyroidism. This was highest in toxic nodules (90.1%), compared with Graves' disease (73.8%) and toxic MNG (75.5%). In patients with Graves' disease, higher administered activity was associated with remission (p = .035). There was a weak inverse correlation between the Tc-99m pertechnetate uptake vs prescribed activity in Graves' disease (r = -0.33; p = .009). Only one patient (0.7%) had an I-131 induced flare of thyrotoxicosis. CONCLUSION: Traditional empiric I-131 prescription is a safe and effective treatment of hyperthyroidism and suitable for most patients. However, there may be a role for personalized I-131 prescription by theranostic guidance in selected patients with high thyroid hyperactivity.

Demonstrating time sequence and extent of sustained decrease in native heart ejection fraction after heterotopic transplantation.

BACKGROUND: In this study we investigate the time sequence and extent of the sustained decrease in native heart ejection fraction (EF) after heterotopic heart transplantation (HHTx) when using gated cardiac blood pool scanning (GCBPS) and transthoracic echocardiography (TTE) One case report of 2 patients used post-operative GCBPS and TTE and found a significant deterioration in native heart EF post-operatively over the course of several years. Comparison with pre-operative measurements using these techniques in a series of patients has not been performed previously. METHODS: Thirteen of 16 HHTx patients with adequate pre- and post-operative GCBPS follow-up were included in this study. All patients also underwent TTE post-operatively and the GCBPS results were correlated with the TTE findings. RESULTS: GCBPS demonstrated a marked (21.1 +/- 4.7% vs 10.5 +/- 3.7%, p < 0.0001) decrease in native EF post-HHTx. Spontaneous echo contrast in the native left ventricle and/or poor opening of the mitral/aortic valves was noted at Day 1 in 4 of 5 patients who had a TTE at this stage. No further decline was noted between the first and last post-operative GCBPS (10.8 +/- 3% vs 8.6 +/- 2.1%, p = NS). CONCLUSIONS: A dramatic decrease in native heart EF post-HHTx occurs as early as Day 1 post-transplant. Dissociation of ventricular contraction is the most likely cause. Studies have demonstrated that paced linkage (counterpulsation) between the ventricles results in improved hemodynamics. This may have clinical implications as to the timing of ejection of blood from a left ventricular assist device (LVAD) and for providing the best hemodynamics for the ventricle being assisted and for optimizing its chances of long-term recovery.

The utility of Tc-99m dextran in the diagnosis and identification of melanoma metastases responsible for protein-losing enteropathy.

Protein-losing enteropathy is an uncommon syndrome of excessive loss of protein via the gastrointestinal mucosa. Tc-99m dextran is a tracer ideally suited for diagnosis and localization. The authors report a case of melanoma mestastases to the small bowel that were causing protein-losing enteropathy. These were diagnosed and localized using Tc-99m dextran, leading to a curative resection.